Driehaus Capital Management LLC Takes $1.28 Million Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Driehaus Capital Management LLC bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 220,264 shares of the company's stock, valued at approximately $1,284,000. Driehaus Capital Management LLC owned 0.38% of Olema Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. KLP Kapitalforvaltning AS bought a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at $30,000. Hsbc Holdings PLC bought a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at $58,000. Teacher Retirement System of Texas bought a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at $60,000. Virtus ETF Advisers LLC raised its holdings in shares of Olema Pharmaceuticals by 43.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company's stock valued at $62,000 after purchasing an additional 3,185 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at $62,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Olema Pharmaceuticals Stock Down 0.5%

NASDAQ OLMA traded down $0.03 during midday trading on Friday, hitting $4.67. The company had a trading volume of 201,436 shares, compared to its average volume of 860,777. The stock has a market cap of $318.90 million, a price-to-earnings ratio of -2.13 and a beta of 2.03. The firm has a fifty day simple moving average of $4.29 and a two-hundred day simple moving average of $6.17. Olema Pharmaceuticals, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13. As a group, equities analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. JPMorgan Chase & Co. dropped their target price on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday, March 28th. The Goldman Sachs Group dropped their target price on shares of Olema Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a report on Monday, April 28th. Finally, Oppenheimer dropped their target price on shares of Olema Pharmaceuticals from $25.00 to $22.00 and set an "outperform" rating on the stock in a report on Wednesday.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.